Status:
COMPLETED
A Randomized Trial Evaluating Personalized vs Guideline-based Well Follow-up Strategies for Patients With Early-stage Breast Cancer
Lead Sponsor:
Ottawa Hospital Research Institute
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE4
Brief Summary
After breast cancer patients complete the acute phase of their treatment (i.e. surgery, chemotherapy and/or radiation therapy), they are routinely followed in clinic every 3-6 months for several years...
Detailed Description
After breast cancer patients complete the acute phase of their treatment (i.e. surgery, chemotherapy and/or radiation therapy), they are routinely followed in clinic every 3-6 months for several years...
Eligibility Criteria
Inclusion
- Being referred to the Wellness Beyond Cancer Program (WBCP) for routine follow-up after completion of acute phase of treatment for invasive breast cancer
Exclusion
- History of prior invasive breast cancer, recurrent brest cancer or metastatic breast cancer
- Currently receiving zoledronate, LHRH (Gonadotropin-releasing hormone) or abemaciclib
Key Trial Info
Start Date :
August 19 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 15 2025
Estimated Enrollment :
261 Patients enrolled
Trial Details
Trial ID
NCT05365230
Start Date
August 19 2022
End Date
August 15 2025
Last Update
November 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada, K1H8M2